Immunogenicity, Efficacy and Safety of QazCovid-in® COVID-19 Vaccine

Inclusion Criteria: Availability of signed and dated informed consent of the volunteer to participate in the study. Healthy male and female volunteers aged 18 and above. Ability and voluntary desire to independently keep records in the Self-Observation Diary, as well as to carry out all the repeated visits provided for in the study for control medical observation. The voluntary desire of females to use methods of reliable contraception throughout the entire period of their participation in the study. Negative results for IgM and IgG antibodies to SARS-CoV-2. Absence of COVID-19 diagnosis in history. Absence in the last 14 days of close contact with persons suspected of being infected with SARS-CoV-2, or persons whose diagnosis of COVID-19 has been confirmed with laboratory. Exclusion Criteria: Aggravated allergic history, drug intolerance, including hypersensitivity to any of the components of the study drug, as well as a history of serious adverse events during vaccine administration (such as allergic reactions, respiratory failure, angioedema, abdominal pain). Acute illness with a fever (body temperature ≥37.1 ° C) at the time of screening. History of chronic alcohol abuse and/or drug use. Positive results for antibodies IgM, IgG to SARS-CoV-2 Women with a positive urine pregnancy test. Simultaneous treatment with immunosuppressive drugs, incl. corticosteroids (2 weeks) 4 weeks prior to study drug administration. Acute or chronic clinically significant lesions of t…